Results 91 to 100 of about 11,032 (258)

Telomere Length of Peripheral Blood Leukocytes Predicts Disease Severity and Worse Survival in Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective Peripheral blood leukocyte telomere length (PBL‐TL) shortening is associated with systemic sclerosis–related interstitial lung disease (SSc‐ILD). However, its association with other organ involvement, disease severity, and survival remains unclear.
Monica M. Yang, Shuo Liu, Michael Wax II, Seoyeon Lee, Sarah French, Paul J. Wolters, Francesco Boin   +6 more
wiley   +1 more source

Nintedanib in systemic sclerosis treatment: a case report

Journal of Medical Case Reports
Background Nintedanib was approved for the treatment of scleroderma and scleroderma-related interstitial lung disease, as it decrease the forced expiratory volume. Case presentation A 48-year-old Asian female patient with systemic scleroderma 6 years ago
Maysoun Kudsi, Raghad Tarcha, Naram Khalayli   +2 more
doaj   +1 more source

Mistaken identity: normotensive scleroderma renal crisis [PDF]

BMJ Case Reports, 2014
A patient presented with neuromuscular, respiratory and cardiac symptoms and was initially diagnosed with amyotrophic lateral sclerosis (ALS), myocardial ischaemia and pneumonia. He developed unexplained progressive kidney failure over the ensuing week, and his kidney biopsy showed thrombotic microangiopathy that led to the correct diagnosis of ...
Arwa, Aburizik, Siddharth, Singh, Laith, Al-Rabadi, Christopher, Blosser   +3 more
openaire   +2 more sources

UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis [PDF]

, 2016
The UK Scleroderma Study Group developed guidelines on the diagnosis and management of scleroderma renal crisis (SRC) based on best available evidence and clinical experience.
Burns, A, Denton, CP, Harber, M, Lynch, BM, Ong, V, Stern, EP   +5 more
core  

Linezolid prevents fibroblast activation and ameliorates tissue fibrosis by inhibition of mitochondrial translation

Arthritis &Rheumatology, Accepted Article.
Background Beyond its role as a ribosome‐targeting antibiotic, linezolid was recently shown to modulate immune responses by inhibiting mitochondrial translation. Since mitochondrial dysfunction is implicated in various fibrotic diseases, including systemic sclerosis (SSc), this study aimed to evaluate the antifibrotic potential of linezolid and ...
Xuezhi Hong, Yanhua Xiao, Haodong Qi, Shihao Zhu, Tim Filla, Andrea‐Hermina Györfi, Yi‐Nan Li, Meilin Xu, Langxian Zhi, Thuong Trinh‐Minh, Clara Dees, Georg Schett, Jörg H.W. Distler, Alexandru‐Emil Matei   +13 more
wiley   +1 more source

Long‐Term Outcomes of Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Systemic Sclerosis Patients with Impaired Cardiac Function

Arthritis &Rheumatology, Accepted Article.
Objective High intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with advanced SSc. The role of reduced intensity conditioning (RIC) prior to AHSCT in this population remains unclear. We conducted this study to determine the long‐term outcomes of RIC AHSCT in SSc patients with cardiac ...
Yonatan Lean, Carrie Richardson, Anthony Esposito, Katy Bedjeti, George E. Georges   +4 more
wiley   +1 more source

Kidney involvement in systemic sclerosis [PDF]

Beyond Rheumatology, 2019
Kidney involvement in systemic sclerosis (SSc) is primarily manifested by scleroderma renal crisis (SRC). More than 30 years ago, it was the main cause of death in these patients.
Angelo De Cata, Michele Inglese, Francesca Molinaro, Renato Carignola   +3 more
doaj   +1 more source

Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. [PDF]

, 2017
Systemic sclerosis (SSc) is a rare disabling autoimmune disease with a similar mortality to many cancers. Two randomized controlled trials of autologous hematopoietic stem cell transplantation (AHSCT) for SSc have shown significant improvement in organ ...
A Gabrielli, A-L Hachulla, AJ Tyndall, B Sandmeier, BH Bulkley, C Denton, C Ferri, C Meune, C Meune, C Nannini, CJ Valerio, CS Desai, D C Lee, D Farge, D Farge, D G Kiely, D Launay, D Mukerjee St, DC Lee, DG Kiely, DP Tashkin, E Di Cesare, E Hachulla, E Mousseaux, F Grothues, F van den Hoogen, G Lefèvre, GE Tzelepis, GP Bezante, H Baumgartner, J A Snowden, J Avouac, J de Vries-Bouwstra, J Fransen, J Hurdman, JA Snowden, JC Plana, JD Rich, JG Coghlan, JM van Laar, JPA Ioannidis, JS Arkles, KH Yiu, L Chung, L Scussel-Lonzetti, LG Rudski, M Elhai, M Henein, M Rovira, M-C Oliveira, MC Oliveira, MH Williams, MR Fisher, N Del Papa, N Galiè, NAB Ntusi, P Clements, P de Groote, R Condliffe, R K Burt, R Saccardi, R Saccardi, RA Nishimura, RK Burt, RK Burt, RK Burt, RT Domsic, S Bae, S J Shah, S Jacobsen, S Mavrogeni, SC Mathai, SD Solomon, SJ Shah, SJ Shah, SLF Walsh, T Alexander, T Alexander, WA D’Angelo, WA Zoghbi, Y Allanore, Z Marjanovic   +81 more
core   +1 more source

Impact of evolving treatment patterns on interstitial lung disease progression in systemic sclerosis using the EUSTAR database

Arthritis &Rheumatology, Accepted Article.
Background The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasing immunosuppressive (IST) and anti‐fibrotic therapies available. However, their real‐world use remains unclear. Objectives To analyze treatment trends and the effect of IST and anti‐fibrotic therapies on ILD progression ...
Corrado Campochiaro, Marie‐Elise Truchetet, Madelon Vonk, Giacomo De Luca, Giovanna Cuomo, Lidia P. Ananieva, Eric Hachulla, Vanessa Smith, Ana Maria Gheorghiu, Radim Becvar, Patricia Carreira, Nicolas Hunzelmann, Daniel E. Furst, Vera Ortiz‐Santamaria, Francesco Del Galdo, Marco Matucci‐Cerinic, Anna‐Maria Hoffmann‐Vold, EUSTAR collaborators   +17 more
wiley   +1 more source

Scleroderma renal crisis: pathogenesis issues, disease pattern and modern approaches to the treatment

Počki, 2018
Scleroderma renal crisis (SRC) is a major complication in patients with systemic sclerosis. SRC occurs in about 5–25 % of all patients with scleroderma. It is characterized by malignant hypertension and olig-/anuric acute renal failure.
I.Yu. Golovach, Ye.D. Yehudina
doaj   +1 more source